Metabolic

Latest Features

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

In a meta-analysis of cross-sex hormone therapy use in transgender individuals, researchers found that transgender women may have a greater risk for CVD mortality vs cisgender women in the general population.

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.

New Recommendation for Glucose-Lowering Drug Clinical Trials

New Recommendation for Glucose-Lowering Drug Clinical Trials

The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.

Understanding Obesity's Role in Atrial Fibrillation

Understanding Obesity's Role in Atrial Fibrillation

The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Physical Activity for Diabetes: ADA Updated Guidelines

Physical Activity for Diabetes: ADA Updated Guidelines

Physical activity guidelines were updated for patients with type 2 diabetes, type 1 diabetes, and prediabetes.

Hope for Heart Failure in Thyroid Hormone Therapy

Hope for Heart Failure in Thyroid Hormone Therapy

Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Reducing the Progression of Coronary Heart Disease With Estradiol

Reducing the Progression of Coronary Heart Disease With Estradiol

In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.

Latest News

Acute MI With Diabetes Mortality Predicted by Acute-to-Chronic Glycemic Ratio

Acute MI With Diabetes Mortality Predicted by Acute-to-Chronic Glycemic Ratio

In patients with diabetes who had an acute myocardial infarction, the acute-to-chronic glycemic ratio was a better predictor of mortality compared with baseline glycemia levels.

Expanded Use of TIMI Risk Score for CV Event Prediction in Diabetes

Expanded Use of TIMI Risk Score for CV Event Prediction in Diabetes

The expanded use of TIMI Risk Score for Secondary Prevention in patients with T2D may be helpful to predict risk for CV events accurately.

Hypertension Risk Increased With Subclinical Primary Aldosteronism

Hypertension Risk Increased With Subclinical Primary Aldosteronism

Renin-independent aldosteronism, and possibly mineralocorticoid receptor activation increase risk for hypertension.

Cardiovascular Events and Mortality With GLP-1 Receptor Agonists

Cardiovascular Events and Mortality With GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists can reduce major adverse cardiovascular events in patients with type 2 diabetes.

CVD, Mortality May Be Affected by Visit-to-Visit Fasting Plasma Glucose Variability

CVD, Mortality May Be Affected by Visit-to-Visit Fasting Plasma Glucose Variability

Patients with visit-to-visit variability of fasting plasma glucose may have a higher risk of developing cardiovascular disease and all-cause mortality.

Semaglutide Approved for Adults With Type 2 Diabetes

Semaglutide Approved for Adults With Type 2 Diabetes

The FDA has approved semaglutide injection for the treatment of type 2 diabetes in adults.

Cardiovascular Outcomes With Insulin-Induced Weight Gain in T2D

Cardiovascular Outcomes With Insulin-Induced Weight Gain in T2D

Weight gain associated with insulin therapy is not associated with adverse cardiovascular outcomes in people with type 2 diabetes.

Cardiovascular Risks With Severe Hypoglycemia in Type 2 Diabetes

Cardiovascular Risks With Severe Hypoglycemia in Type 2 Diabetes

The study investigates the correlation between hypoglycemia and the risk for all-cause mortality in patients with type 2 diabetes.

High-Dose Beta-Blockers Associated With Lower Mortality in HF, Diabetes

High-Dose Beta-Blockers Associated With Lower Mortality in HF, Diabetes

Patients with chronic heart failure and diabetes may have a greater reduction in mortality with higher beta-blocker doses.

Sleep Debt Affects Cardiovascular Health in Older Women

Sleep Debt Affects Cardiovascular Health in Older Women

Obesity, hypertension, and circadian misalignment may all result from sleep debt.

Sign Up for Free e-Newsletters